

Healthcare Services


Quarterly Update | Q2 2023



MNPCF.ca


Industry Overview M&A Transactions & Performance





North American

Above noted mid-market M&A activity includes disclosed transactions not exceeding a total transaction value of \$500 million.



Healthcare merger and acquisition (M&A) activity in Q2 2023 exceeded \$4.8 billion in disclosed transaction value across 383 deals in Canada and the United States (U.S.). The average deal size among disclosed transactions was \$54 million, a decrease from \$67.2 million in Q1 2023.

In Canada, the top healthcare sub-sectors for deal activity in the quarter were healthcare services (23%), drug retail (15%), biotechnology (15%) and pharmaceuticals (13%).

During the YTD 2023, healthcare multiples cooled on markedly lower year-over-year volume. Some of the concern is attributed to corporate performance, increased macro-economic uncertainty (inflation, labor availability, persisting supply chain issues, and the prospect of a recession), and increased borrowing charges / interest rates.

During the YTD 2023, EV/EBITDA multiples for the healthcare services industry averaged 9.5x across all transactions. For lower mid-market transaction values (\$10-25 million range), the EV/EBITDA multiple averaged 5.4x.

Market Update Articles



Alberta seeing 'crisis' in veterinarian staff shortages, emergency animal care ¹

- July 11, 2023: Edmonton animal rescue group describes 'unbelievable' shortage of vet services.
- Pet owners and veterinarians worldwide are raising concerns about the scarcity of veterinary professionals, a problem that has been further magnified by the COVID-19 pandemic. They emphasize that urgent measures are required to address this issue and provide short-term relief.

Big Pharma dealmaking recovers with \$85bn M&A splurge ²

- June 11, 2023: In the first five months of the year, pharmaceutical and biotech companies invested a substantial \$85 billion in acquisitions, signifying a remarkable rebound in the industry.
- The significant increase in M&A is evident when comparing it to the \$35.6 billion in deals during the same period in 2022 and \$49.1 billion the year before. This surge is primarily driven by the substantial cash reserves accumulated by big pharmaceutical companies during the pandemic.
- Pfizer, Merck, and Sanofi have taken the lead in the M&A revival this year, as they have made headlines by announcing multi-billion dollar acquisitions. This comes as dealmaking across other market sectors has fallen sharply due to rising interest rates and tightening bank lending.

B.C. pharmacists set to treat minor ailments, prescribe contraceptives starting June 1³

- May 31, 2023: Pharmacists in British Columbia (B.C.) will have more responsibilities, starting June 1, in an effort to improve access for those without a family doctor and ease the stress on an overburdened health system.
- The College of Pharmacists of B.C. says 75 percent of eligible community pharmacists have completed the training required to diagnose and prescribe medications for 21 minor ailments like acne, shingles, or urinary tract infections, as well as prescribe contraception.
- Health Minister, Adrian Dix says the new services will make it easier and faster for patients to get medication and take the pressure off nurses and doctors who can focus on those with more complex needs.
- The association says the province is one of the last in Canada to give pharmacists the ability to prescribe for minor ailments but one of the first to allow them to prescribe contraception.

Source 2: https://www.ft.com/content/e03d746c-e74c-4e95-8d12-d1edef2880d7

Source 1: https://www.cbc.ca/news/canada/edmonton/alberta-seeing-crisis-in-veterinarian-staff-shortages-emergency-animal-care-1.6902128

Source 3: https://www.cbc.ca/news/canada/british-columbia/bc-pharmacists-new-responsibilities-1.6861353

Market Update Select Recent M&A Transactions



FGC HEALTH	Closed	April 12, 2023
has acquired	Transaction Value	Not disclosed
	TEV/EBITDA	Not disclosed
	Location (Vendor)	Pouce Coupe, B.C.

- FGC Health owns, operates, and services independent pharmacies, medical clinics, home health care, and ambulatory care services.
- RNN Medical Division provides emergency medical services via its Mobile Treatment Centres.
- MNP Corporate Finance Inc. acted as exclusive financial advisor to RNN Medical Division in structuring and negotiating this transaction.

Valence	Closed	May 8, 2023
has acquired	Transaction Value	\$63.4MM
	TEV/EBITDA	Not disclosed
	Location (Vendor)	Montreal, QC

- Valence Discovery develops a platform using artificial intelligence to streamline pharmaceutical R&D. It focuses on preclinical toxicology.
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company. By combining advancements in biology, chemistry, automation, data science, and engineering, the company aims to streamline the process of drug discovery and make it more efficient and industrialized.

Neighbourly Announces Agreements to Acquire 10 Pharmacies During the Quarter²

- May 25, 2023: Neighbourly Pharmacy Inc. (TSX: NBLY) (Neighbourly), one of Canada's largest and fastestgrowing network of independent pharmacies, announced that it has entered into a binding agreement to acquire three pharmacies in Ontario from a single seller.
- June 6, 2023: Neighbourly announced that it has entered into a binding agreement to acquire seven pharmacies from a single seller, five of them located in Saskatchewan and two in British Columbia.
- Upon completion of these acquisitions, Neighbourly's network will comprise a total of 294 locations across Canada.

Source 1: Capital IQ. Data as of June 30, 2023.

Source 2: https://investors.neighbourlypharmacy.ca/news/news-details/2023/Neighbourly-Announces-Agreement-to-Acquire-Seven-Pharmacies-in-Western-Canada/default.aspx

https://investors.neighbourlypharmacy.ca/news/news-details/2023/Neighbourly-Announces-Agreement-to-Acquire-Three-Pharmacies-in-Ontario/default.aspx


Industry Overview



Pharmacies and Drug Stores in Canada

The pharmacy and drug store industry includes the retailing of prescription and over-the-counter medications, health and beauty items, toiletries, and consumable goods directly to consumers.


Industry Glance 2022 Revenue **\$54.1 billion** Annual Growth 2018 – 2023 **0.5%** Projected Annual Growth 2023 – 2028 **2.2%** Number of Businesses in 2023 Products and Services Segmentation (2023)



- Prescription pharmaceuticals
- Non-prescription pharmaceuticals
- Personal and beauty products
- Other

Dentists in Canada

The dental services industry in Canada is comprised of establishments of licensed dentists primarily engaged in the private or group practice of general or specialized dentistry or dental surgery.



Page 5

Industry Overview




Veterinarian Services in Canada

The veterinarian services industry in Canada is comprised of veterinarians who provide medical, dental, and surgical treatments for animals. This industry also includes companies that provide laboratory and diagnostic testing for veterinary practitioners.




Products and Services Segmentation (2022)



- Non-surgical procedures
- Routine exams
- Laboratory and diagnostic testing
- Other

Optometrists in Canada


The optometrist industry in Canada is comprised of establishments of licensed optometrists primarily engaging in eye examinations and the prescription of eyeglasses, contact lenses, and eye exercises.





Macroeconomic Indicators




The healthcare industry is affected by a number of key macroeconomic growth drivers. Below, we highlight total public and private healthcare expenditure, per capita disposable income, the aging population in Canada, and national unemployment rates.












Public Comparable Analysis

Growth, Margins & Multiples




4%




LTM EBITDA Margin






NTM EBITDA Margin



LTM EV/EBITDA



Source: Capital IQ. Data as of June 30, 2023. Valuation details provided on page 9. "LTM" refers to last twelve months. "NTM" refers to next twelve months.

NTM EV/EBITDA



15x


10x

AVG: 10.0x

Public Comparable Analysis








Retail Pharmacy

Healthcare/Dental Equipment



Healthcare Service Providers

Pharmaceutical Distributors

Pharmaceuticals

Public Comparable Analysis Trading Multiples & Operating Statistics



We have selected a group of publicly traded healthcare entities for this high-level analysis. These public companies help act as a proxy for the industry and provide strong industry context.

		Enterprise Value	LTM Operating Figures			NTM Consensus Estimates			Valuation		
Company	Market Capitalization		Revenue	Revenue Growth	EBITDA	EBITDA Margin	Revenue Growth	EBITDA Margin	NTM EV/EBITDA	LTM EV/EBITDA	LTM EV/RE\
Retail Pharmacy						ý		<u> </u>			
CVS Health Corporation	\$117,359	\$195,429	\$446,378	10.4%	\$30,196	6.8%	3.0%	5.7%	7.4x	6.6x	0.4x
Rite Aid Corporation	\$110	\$8,115	\$31,890	(2.8%)	\$1,463	4.6%	(5.8%)	1.5%	17.4x	5.6x	0.3x
CareRx Corporation	\$130	\$225	\$380	22.2%	\$25	6.5%	0.4%	8.5%	6.9x	9.1x	0.6x
Neighbourly Pharmacy Inc.	\$714	\$1,013	\$749	75.2%	\$74	9.8%	23.7%	10.9%	10.0x	13.7x	1.4x
Median	\$422	\$4,564	\$16,320	16.3%	\$768	6.6%	1.7%	7.1%	8.7x	7.9x	0.5x
Mean	\$29,578	\$51,195	\$119,849	26.3%	\$7,939	6.9%	5.3%	6.7%	10.4x	8.8x	0.7x
Pharmaceuticals											
ohnson & Johnson	\$569,595	\$607,062	\$130,245	1.5%	\$45,462	34.9%	0.4%	35.9%	12.9x	13.6x	4.8x
Merck & Co., Inc.	\$387,719	\$414,774	\$78,297	7.2%	\$30,715	39.2%	(0.5%)	39.4%	12.7x	13.8x	5.4x
Pfizer Inc.	\$274,202	\$295,998	\$125,764	0.6%	\$57,063	45.4%	(30.4%)	37.0%	9.2x	5.3x	2.4x
√iatris Inc.	\$15,846	\$40,268	\$21,378	(10.5%)	\$7,366	34.5%	(2.8%)	32.7%	5.9x	5.6x	1.9x
Bausch Health Companies Inc.	\$3,853	\$31,767	\$11,027	(2.1%)	\$3,811	34.6%	0.6%	36.1%	7.9x	8.5x	2.9x
Median	\$274,202	\$295,998	\$78,297	0.6%	\$30,715	34.9%	(0.5%)	36.1%	9.2x	8.5x	2.9x
Mean	\$250,243	\$277,974	\$73,342	(0.7%)	\$28,884	37.7%	(6.6%)	36.2%	9.7x	9.4x	3.5x
Pharmaceutical Distributors											
Walgreens Boots Alliance, Inc.	\$32,568	\$92,034	\$184,939	1.2%	\$9,846	5.3%	2.1%	4.0%	11.8x	9.6x	0.5x
McKesson Corporation	\$76,679	\$80,653	\$374,393	4.8%	\$7,393	2.0%	3.7%	1.8%	11.5x	11.1x	0.2x
AmerisourceBergen Corporation	\$51,469	\$58,029	\$334,928	7.8%	\$4,889	1.5%	3.1%	1.5%	11.5x	12.1x	0.2x
Cardinal Health, Inc.	\$31,883	\$32,871	\$268,792	12.3%	\$3,338	1.2%	7.1%	1.2%	9.2x	10.1x	0.1x
Median	\$42,018	\$69,341	\$301,860	6.3%	\$6,141	1.7%	3.4%	1.6%	11.5x	10.6x	0.2x
Mean	\$48,150	\$65,897	\$290,763	6.5%	\$6,366	2.5%	4.0%	2.1%	11.0x	10.7x	0.3x
Healthcare Service Providers											
HCA Healthcare, Inc.	\$110,550	\$166,644	\$82,370	1.9%	\$17,951	21.8%	2.9%	19.6%	10.0x	9.5x	2.1x
Universal Health Services, Inc.	\$14,662	\$21,558	\$18,366	5.0%	\$2,466	13.4%	2.7%	12.1%	9.4x	8.9x	1.2x
Fenet Healthcare Corporation	\$10,985	\$34,673	\$26,608	(0.0%)	\$5,385	20.2%	0.4%	16.6%	7.8x	6.6x	1.3x
Community Health Systems, Inc.	\$764	\$17,941	\$16,518	(2.1%)	\$1,981	12.0%	(0.1%)	12.3%	8.8x	9.3x	1.1x
Median Mean	\$12,823 \$34,240	\$28,116 \$60.204	\$22,487 \$35,965	1.0% 1.2%	\$3,925 \$6,946	16.8% 16.9%	1.6% 1.5%	14.4% 15.1%	9.1x 9.0x	9.1x 8.6x	1.3x 1.4x
		\$00,20-F	\$33,303	1.2.70	¥0,540	10.370	1.370	13.170	5.00	0.0x	1.77
Healthcare/Dental Equipment & Sup Becton, Dickinson and Company	pplies \$99,292	\$120,796	\$25,449	(0.6%)	\$6,688	26.3%	2.9%	27.6%	16.6x	18.5x	4.8x
Baxter International Inc.	\$30,518	\$50,749	\$20,370	11.1%	\$4,445	21.8%	(0.4%)	21.9%	11.4x	11.7x	2.5x
dentalcorp Holdings Ltd.	\$1,379	\$2,644	\$1,328	24.8%	\$203	15.3%	10.8%	18.5%	9.7x	13.0x	2.0x
DENTSPLY SIRONA Inc.	\$11,260	\$13,922	\$5,319	(5.8%)	\$937	17.6%	(1.6%)	19.1%	13.9x	15.2x	2.7x
Henry Schein, Inc.	\$14,069	\$17,721	\$16,951	(1.0%)	\$1,657	9.8%	0.9%	8.8%	11.7x	10.9x	1.1x
Patterson Companies, Inc.	\$4,197	\$4,828	\$8,776	(0.4%)	\$547	6.2%	0.6%	5.8%	9.3x	9.0x	0.6x
Median	\$12,664	\$15,821	\$12,863	(0.5%)	\$1,297	16.5%	0.8%	18.8%	11.6x	12.3x	2.3x
Mean	\$26,786	\$35,110	\$13,032	4.7%	\$2,413	16.2%	2.2%	17.0%	12.1x	13.0x	2.3x

Source: Capital IQ. Data as of June 30, 2023. "LTM" refers to last twelve months. "NTM" refers to next twelve months.

About Us

CORPORATE FINANCE INC.


MNP Corporate Finance (MNPCF) has a dedicated team of over 100 M&A, capital markets, and due diligence professionals across Canada. MNPCF works with clients in virtually all industries as they prepare, plan, and execute transactions.

Our typical transactions range in value between \$3 million and \$300 million.

Local and International Reach

MNP is a participating firm within Praxity, a unique global alliance of independent accounting/advisory firms created to answer global business needs. As a member of Praxity, we are able to offer access to corporate finance, accounting and tax advisory services worldwide. We are also affiliated with Corporate Finance Cross Border, which consists of 250+ M&A professionals in more than 30 countries.





Services

- Divestitures
- Acquisitions
- Debt Financing
- Due Diligence
- Transaction Advisory Services






About Us



Deal Experience

Since our inception, our team has advised on hundreds of transactions, in a wide range of industries with diverse enterprise values. In the past ten years alone, we have completed over 250 transactions worth over \$4.5 billion (not including due diligence engagements).

Recently Closed Deals (National)



Industry Experience

- Food & Beverage
- Retail & Distribution
- Manufacturing
- Agriculture
- Automotive
- Materials
- Health Care
- Pharmaceutical

- Transportation
- Construction
- Software
- Financial Services
- Technology
- Energy
- Oilfield Services
- Real Estate

Hands-on Approach

Current M&A transactions require a hands-on approach from start to finish including the active engagement of senior resources. Our senior resources are dedicated to our clients and are available as necessary and appropriate. We keep our clients regularly informed of the engagement status, issues we are encountering, successes, and overall progress.

Integrated Service Offering

We draw on the vast experience and deep specialist knowledge network of our partners locally, nationally and internationally as specialty issues arise, such as pre-transaction tax planning, transaction structuring, estate planning, valuation, due diligence, performance improvement, and risk management.

Leadership Team





Brett Franklin President Winnipeg Brett.Franklin@mnp.ca 204.336.6190

Erik St-Hilaire

Managing Director

Winnipeg

Erik.St-Hilaire@mnp.ca

204.336.6200



Aleem Bandali Managing Director Vancouver Aleem.Bandali@mnp.ca 778.374.2140

Stephen Shaw

Managing Director

Toronto

Stephen.Shaw@mnp.ca

416.515.3883

Transaction Leadership



Bryce Davis Managing Director Vancouver Bryce.Davis@mnp.ca 604.637.1514



Mike Reynolds Managing Director Calgary Mike.Reynolds@mnp.ca 587.702.5909



Managing Director Calgary Mark.Reynolds@mnp.ca 403.536.5548

Jon Edgett

Managing Director

Waterloo

Jon.Edgett@mnp.ca

519.772.7460

Frédéric Fortin

Managing Director

Chicoutimi

Frederic.Fortin@mnp.ca

418.696.4561



Mark Regehr Managing Director Edmonton Mark.Regehr@mnp.ca 780.969.1404



Patrick Khouzam Managing Director Montreal Patrick.Khouzam@mnp.ca 514.228.7874



Managing Director Halifax Craig.Maloney@mnp.ca 902.493.5430





Jean-Raymond Lafond

Managing Director

Drummondville

819.473.7251

Jean-Raymond.Lafond@mnp.ca Éric.Grondin@mnp.ca

Johnny Earl Managing Director Vancouver Johnny.Earl@mnp.ca 604.637.1504



Éric Grondin

Managing Director

Sherbrooke

819.823.3290

Jonathan Conly Managing Director Vancouver 604.637.1516



Kevin Tremblay Managing Director Toronto Kevin.Tremblay@mnp.ca 647.943.4051



Jasmin Allard Managing Director Sherbrooke Jasmin.Allard@mnp.ca 819.560.7856

Due Diligence Leadership



John Caggianiello Managing Director Toronto Jonathan.Conly@mnp.ca John.Caggianiello@mnp.ca 416.513.4177



Wilson Lai Managing Director Toronto Wilson.Lai@mnp.ca 289.695.4386



Saad Arif Managing Director Toronto Saad.Arif@mnp.ca 647.943.4104



David Cyr Managing Director Montreal David.Cyr@mnp.ca 514.884.1764

Divestitures | Financing | Due Diligence

MNPCF.ca

416.596.1711

Jonathan Banford Managing Director Chicoutimi Jonathan.Banford@mnp.ca



Chris Chapman

Managing Director

Toronto

Chris.Chapman@mnp.ca

418.696.3924



